Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with > 5 years of follow-up in patients with advanced renal cell carcinoma (aRCC)-MedSci.cn

Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with > 5 years of follow-up in patients with advanced renal cell carcinoma (aRCC)

Motzer, RJ; Tykodi, SS; Escudier, B; Oudard, S; Hammers, HJ; McDermott, DF; George, S; Castellano, D; Choueiri, TK; Alva, AS; Richardet, ME; Plimack, ER; Srinivas, S; Procopio, G; Donskov, F; Gurney, H; Tomita, Y; McHenry, MB; Saggi, SS; Tannir, NM

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (6):

科室
- - 订阅+
  - 更多科室
工具
服务

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with > 5 years of follow-up in patients with advanced renal cell carcinoma (aRCC)

科室

工具

服务